Aug. 11, 2026
CAMBRIDGE, MASSACHUSSETTS — Skylark Bio, a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss and other monogenic disorders, announced that the first patient has been dosed in the SONIX Phase 1/2 clinical trial evaluating SKY-GJB2, the company’s investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. “Dosing the first patient in SONIX brings us one step closer to a future
















